During the Drug Company Working Group session at the recent American Academy of Neurology annual meeting in Vancouver, Canada, a top researcher from Cytokinetics gave an update on a new Phase 3 study of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis (ALS), and another from Biogen talked about a new trial to assess outcome measures in ALS…
News
Mutations in the SOD1 gene, a major copper-binding protein, are a known cause of familial amyotrophic lateral sclerosis (ALS). An extensive review from Keio University in Japan explores the possible role of copper homeostasis in SOD1-linked ALS, as seen in mice studies, and highlights the need for similar studies in people.
Scientists at Umeå University have found that superoxide dysmutase (SOD1), a protein that may cause amylotophic lateral sclerosis (ALS) spreads and clumps when injected into mice. The protein deposits also cause ALS-like symptoms. The report, titled “Two superoxide dismutase prion strains transmit amyotrophic lateral sclerosis-like disease” appeared May 3, 2016…
SOD1 protein aggregates can spread in a prion-like way, rapidly causing amyotrophic lateral sclerosis (ALS) when injected into the spinal cord of mice carrying a human mutated SOD1 gene. The results, published in the Journal of Clinical Investigation, substantially advance insights into mechanisms in hereditary ALS, and…
May marks ALS Awareness Month, a grassroots campaign led by the ALS Association to improve understanding of, and raise research money for, amyotrophic lateral sclerosis (ALS). Each May the ALS Association sponsors activities that include National ALS Advocacy Day, leading a delegation of ALS patients, their caregivers, and other advocates to Capitol Hill to urge…
Researchers using a miniature microscope saw that glial cells, called astrocytes, contribute to sensory nerve transmission in the spinal cord of awake and moving animals. Offering unparalleled insights into the workings of the spinal cord, the tool may lead to new treatments for a range of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS).
News
Neuroscientist Receives $25,000 Grant to Develop Way of Helping Advanced ALS Patients to Speak Again
The American Speech-Language-Hearing Foundation has awarded a $25,000 New Century Scholars Research Grant to neuroscientist Jonathan Brumberg to develop a brain-computer interface (BCI) that directly controls existing augmentative and alternative communication (AAC) devices. The platform is expected to aid people with profound speech and motor impairments due to neurodegenerative disorders such as…
University of Florida Health researchers have developed a mouse model of the most common genetic mutation that causes amyotrophic lateral sclerosis (ALS). The model, which captures the molecular, behavioral, and neurodegenerative features of the disease, could greatly aid in the development of more effective therapeutic agents. The paper detailing the model,…
The University of California at San Francisco (UCSF) has announced that a new UCSF Weill Institute for Neurosciences will be established, made possible by $185 million in funding — the largest-ever gift to the university and one of the largest ever made to support the neurosciences in the U.S. —…
Results from the Phase 3 trial of edaravone (MCI-186) in amyotrophic lateral sclerosis (ALS) were presented by Mitsubishi Tanabe Pharma Corporation at the 68th Annual Meeting of the American Academy of Neurology held April 15-21 in Vancouver, British Columbia. The Phase 3 MCI-186-19 clinical study has reportedly met its primary efficacy endpoint of mean change…
Recent Posts
- ALS nerve damage can occur without TDP-43 protein clumps: Study
- Dealing with loss, both big and small, in life with ALS
- Scientists use fat-based ‘bubbles’ to sneak ALS treatment into the brain
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’
- HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001